Oral MIB-626 (β Nicotinamide Mononucleotide) Safely Raises Blood Nicotinamide Adenine Dinucleotide Levels in Hospitalized Patients With COVID-19 and Acute Kidney Injury: A Randomized Controlled Trial.

ABSTRACT: Nicotinamide adenine dinucleotide (NAD⁺) plays an important role in the innate immune response and is depleted during SARS-CoV-2 infection due to increased turnover. It is unknown whether treatment with NAD⁺ precursors can safely raise NAD⁺ levels in patients with COVID-19. To determine whether MIB-626 (β-nicotinamide mononucleotide), an NAD⁺ precursor, can safely increase blood NAD⁺ levels and attenuate acute kidney injury (AKI) and inflammation in hospitalized patients with COVID-19, 42 adults, ≥ 18 years, hospitalized with COVID-19 and AKI, were randomized in a 3:2 ratio to MIB-626 1.0-g or placebo tablets twice daily for 14 days. Circulating NAD⁺ and its metabolites, markers of AKI, inflammation, and disease sever

SUBMITTER: Pencina KM 

PROVIDER: S-EPMC12312518 | biostudies-literature | 2025 Aug

REPOSITORIES: biostudies-literature